Last updated on December 2017

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy


Brief description of study

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy

Detailed Study Description

This is a multi-site, placebo-controlled, double-blind, randomized-withdrawal study evaluating the durability of clinical benefit of a study drug for patients with symptomatic neurogenic orthostatic hypotension. This study has a duration of up to 36 weeks, consisting of 5 periods:

  1. Screening Period: up to 4 weeks duration;
  2. Open-Label Titration Period (Titration Period): up to 4 weeks duration;
  3. Open-Label Treatment Period (Open-Label Period): 12 weeks duration;
  4. Double-Blind Treatment Period (Double-Blind Period): 12 weeks duration;
  5. Safety Follow-Up Period: 4 weeks duration.

    Clinical Study Identifier: TX148751

    Contact Investigators or Research Sites near you

    Start Over

    EvergreenHealth Research Program

    EvergreenHealth Research Program
    Kirkland, WA USA
      Connect »